Aberrant expression of LAG3, which is interdependent with its ligand FGL-1 and inhibits T-cell function, has been reported to be negatively associated with clinical prognosis in a variety of cancers, including solid tumors and some cancers of hematological origin. Here, FGL1 is linked to cancer.